Aarti A Bhagat¹, Jyoti Y Kamble¹, Gayatri S Magdum¹, Mayuri S Mane¹, Rutuja N Jadhav¹ and Firoj A Tamboli²*

¹UG Students, B. Pharmacy, Bharati Vidyapeeth College of Pharmacy, Near Chitranagari, Kolhapur - 416013 Maharashtra, India ²Department of Pharmacognosy, Bharati Vidyapeeth College of Pharmacy, Near Chitranagari, Kolhapur - 416013 Maharashtra, India

*Corresponding Author: Firoj A Tamboli, Department of Pharmacognosy, Bharati Vidyapeeth College of Pharmacy, Near Chitranagari, Kolhapur - 416013 Maharashtra, India.

Received: November 11, 2025; Published: November 25, 2025

Abstract

Plant-derived compounds or phytochemicals are potential adjuvant or chemopreventive candidates in NF1 by regulating oxidative stress, inflammation, and dysregulated cellular signaling. One of them, the curcumin of Curcuma longa has been confirmed to have antiprolliferative, pro-apoptotic and anti-inflammatory effects in preclinical NF1 models and preliminary case studies indicate that when used with diets rich in polyphenols, tumor-volume reduction was also achieved. Likewise, catechin epigallocatechin-3-gallate (EGCG) the green tea derivative also has antioxidant and signalling modulation properties such as Nrf2 activation which is applicable to NF1 pathogenesis. Resveratrol was also reported to induce cellular differentiation inhibiting cell proliferation in NF1 patient derived cell models. Although these represent promising preclinical results, there is a dearth of clinical evidence, which is mostly small, observational studies. The ongoing trials of nutraceutical interventions are focused on the safety, the most effective dosage, and effectiveness. Potential adverse effects of the trial, including EGCG-associated hepatotoxicity at high doses and poor bioavailability of curcumin are imperative to take into consideration during trial design. All in all, although phytochemicals have promising biological agency and mechanistic applicability in the management of NF1, strong randomized clinical trials are needed to identify their potential therapeutic worth and clinical safety.

Keywords: Cafe-Au-Lait Macules (CALMs); Neurofibromatosis Type 1 (NF1)

References

1. Polack FP., et al. “Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine”. The New England Journal of Medicine27 (2020): 2603-2615.
2. Kalil AC. “Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemics”. JAMA19 (2021): 1897-1898.
3. Dolgin E. “The tangled history of mRNA vaccines”. Nature7876 (2021): 318-324.
4. Topol EJ. “Digital health and the future of medicine: progress, pitfalls, and promise”. Nature Medicine12 (2021): 2009-2014.
5. Gereffi G. “What does the COVID-19 pandemic teach us about global value chains? The case of medical supplies”. Journal of International Business Policy3 (2020): 287-301.
6. So AD and Woo J. “Reserving coronavirus disease 2019 vaccines for global access: cross-sectional analysis”. BMJ 371 (2020): m4750.

Citation

Citation: Satish Eknath Bahekar. “Post-Pandemic Therapeutics: Reimagining Resilience in Global Health". Acta Scientific Pharmaceutical Sciences 9.12 (2025): 01-02.

Copyright

Copyright: © 2025 Satish Eknath Bahekar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.